- Home
- Publications
- Publication Search
- Publication Details
Title
The Discovery and Development of Liraglutide and Semaglutide
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-04-12
DOI
10.3389/fendo.2019.00155
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus
- (2018) Bruno Vergès et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4
- (2018) Alberto Oddo et al. BIOCHEMISTRY
- Bone markers and cardiovascular risk in type 2 diabetes patients
- (2018) Sabine R. Zwakenberg et al. Cardiovascular Diabetology
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease
- (2018) Subodh Verma et al. CIRCULATION
- Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
- (2018) Jessica M. Adams et al. DIABETES
- Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial
- (2018) Michael A Nauck et al. Diabetes & Vascular Disease Research
- A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
- (2018) Ildiko Lingvay et al. DIABETES CARE
- Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
- (2018) Bernard Zinman et al. DIABETES CARE
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- (2018) Bo Ahrén et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
- (2018) Lene Jensen et al. DIABETES OBESITY & METABOLISM
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
- (2018) Seung Pil Yun et al. NATURE MEDICINE
- Fire prevention in the Parkinson’s disease brain
- (2018) Lena Brundin et al. NATURE MEDICINE
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
- (2018) Daniel J. Drucker DIABETES
- The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
- (2018) Ketan Dhatariya et al. DIABETES CARE
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Structure of the glucagon receptor in complex with a glucagon analogue
- (2018) Haonan Zhang et al. NATURE
- Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment
- (2018) Casper Bo Gravesen Salinas et al. Scientific Reports
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
- (2018) Stephen T. Buckley et al. Science Translational Medicine
- Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
- (2017) Lene Jensen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Strategies and industrial perspectives to improve oral absorption of biological macromolecules
- (2017) Chang Liu et al. Expert Opinion on Drug Delivery
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion
- (2017) Caroline K Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques
- (2017) Sarah R. Langley et al. JOURNAL OF CLINICAL INVESTIGATION
- Activation of murine pre-proglucagon–producing neurons reduces food intake and body weight
- (2017) Ronald P. Gaykema et al. JOURNAL OF CLINICAL INVESTIGATION
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Structure of the full-length glucagon class B G-protein-coupled receptor
- (2017) Haonan Zhang et al. NATURE
- Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
- (2017) Yan Zhang et al. NATURE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis
- (2017) Carel le Roux et al. Obesity Facts
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Semaglutide, lipid-lowering drugs, and NAFLD
- (2017) Niki Katsiki et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- The dynamic plasticity of insulin production in β-cells
- (2017) Brandon B. Boland et al. Molecular Metabolism
- The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
- (2017) Laurie L. Baggio et al. Molecular Metabolism
- Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
- (2017) Michael Gejl et al. Scientific Reports
- Human Validation of Genes Associated With a Murine Atherosclerotic PhenotypeHighlights
- (2016) Gerard Pasterkamp et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy
- (2016) Henrik H. Hansen et al. BRAIN RESEARCH
- Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
- (2016) Manfredi Rizzo et al. Cardiovascular Diabetology
- Never Waste a Good Crisis: Confronting Reproducibility in Translational Research
- (2016) Daniel J. Drucker Cell Metabolism
- Parabrachial CGRP Neurons Control Meal Termination
- (2016) Carlos A. Campos et al. Cell Metabolism
- Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease
- (2016) Børge G. Nordestgaard CIRCULATION RESEARCH
- The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice
- (2016) Melissa A. Burmeister et al. DIABETES
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Exposure-response analyses of liraglutide 3.0 mg for weight management
- (2016) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)
- (2016) Eun Ji Park et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- GLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
- (2016) Claus H. Bang-Berthelsen et al. INFLAMMATORY BOWEL DISEASES
- Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R)
- (2016) Dehua Yang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus
- (2016) Joep van der Leeuw et al. Journal of the American Heart Association
- Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
- (2016) Nicolai J. Wewer Albrechtsen et al. Journal of Diabetes Research
- GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
- (2015) Jacqueline A. Koehler et al. Cell Metabolism
- GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
- (2015) Bernardo Yusta et al. DIABETES
- Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
- (2015) Daniel J. Drucker DIABETES
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain
- (2015) Kristy M. Heppner et al. ENDOCRINOLOGY
- Intestinal GLP-1 and satiation: from man to rodents and back
- (2015) R E Steinert et al. INTERNATIONAL JOURNAL OF OBESITY
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial
- (2015) Caroline K. Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Islet α cells and glucagon—critical regulators of energy homeostasis
- (2015) Jonathan E. Campbell et al. Nature Reviews Endocrinology
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice
- (2015) Gunnar Sørensen et al. PHYSIOLOGY & BEHAVIOR
- A Method for Combining RNAscope In Situ Hybridization with Immunohistochemistry in Thick Free-Floating Brain Sections and Primary Neuronal Cultures
- (2015) Tessa M. Grabinski et al. PLoS One
- Structural similarities and differences between the human and the mouse pancreas
- (2015) Jurij Dolenšek et al. Islets
- Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
- (2015) Kine Marita Knudsen Sand et al. Frontiers in Immunology
- Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
- (2015) Simon C. Cork et al. Molecular Metabolism
- Structure of Class B GPCRs: new horizons for drug discovery
- (2014) Andrea Bortolato et al. BRITISH JOURNAL OF PHARMACOLOGY
- Hypothalamic Tanycytes Are an ERK-Gated Conduit for Leptin into the Brain
- (2014) Eglantine Balland et al. Cell Metabolism
- GLP-1 Provoked Severe Hypoglycemia in an Individual With Type 2 Diabetes and a Benign Insulinoma
- (2014) Ronald J. Ruby et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells
- (2014) David J. Brayden et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
- (2014) Laurie L. Baggio et al. JOURNAL OF CLINICAL INVESTIGATION
- Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
- (2014) Stephanie Sisley et al. JOURNAL OF CLINICAL INVESTIGATION
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas
- (2014) Beatrice Waser et al. MODERN PATHOLOGY
- A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
- (2014) Yuko Tashiro et al. PEPTIDES
- Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior
- (2014) Rozita H. Anderberg et al. PHYSIOLOGY & BEHAVIOR
- Effects of GLP-1 in the Kidney
- (2014) Jeppe Skov REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
- (2013) Astrid Plamboeck et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Progress in detecting cell-surface protein receptors: the erythropoietin receptor example
- (2013) Steve Elliott et al. ANNALS OF HEMATOLOGY
- Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
- (2013) Weike Bao et al. Cardiovascular Diabetology
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model
- (2013) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
- (2013) K. Hermansen et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
- (2013) Andrew E. Hogan et al. DIABETOLOGIA
- Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice
- (2013) Niels-Erik Viby et al. ENDOCRINOLOGY
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain
- (2013) Fanny Langlet et al. JOURNAL OF COMPARATIVE NEUROLOGY
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- Drugs derived from phage display
- (2013) Andrew E Nixon et al. mAbs
- Common variants associated with plasma triglycerides and risk for coronary artery disease
- (2013) Ron Do et al. NATURE GENETICS
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
- (2013) Minsuk Kim et al. NATURE MEDICINE
- Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia
- (2013) Martin Lorenz et al. REGULATORY PEPTIDES
- Impact of Diabetes on Cardiovascular Disease: An Update
- (2013) Alessandra Saldanha de Mattos Matheus et al. International Journal of Hypertension
- Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice
- (2012) Lital Rachmany et al. AGE
- Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
- (2012) Changting Xiao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis
- (2012) K. Henriksen et al. BONE
- The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
- (2012) J. Rosenstock et al. DIABETES CARE
- Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight
- (2012) J. Jelsing et al. DIABETES OBESITY & METABOLISM
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
- (2012) T. Forst et al. DIABETIC MEDICINE
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- The Glucagon-Like Peptide-1 Receptor—or Not?
- (2012) Charles Pyke et al. ENDOCRINOLOGY
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
- (2012) LANCET
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Exendin-4 decreases amphetamine-induced locomotor activity
- (2012) Kevin Erreger et al. PHYSIOLOGY & BEHAVIOR
- Functional importance of GLP-1 receptor species and expression levels in cell lines
- (2012) Lotte Bjerre Knudsen et al. REGULATORY PEPTIDES
- Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
- (2012) Jan Terje Andersen et al. Nature Communications
- The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
- (2011) Christoph Kapitza et al. ADVANCES IN THERAPY
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma
- (2011) Dale O. Kiesewetter et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
- (2011) Laszlo Hegedüs et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug
- (2011) Lisbeth V. Jacobsen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of albumin on drug delivery — New applications on the horizon
- (2011) Bakheet Elsadek et al. JOURNAL OF CONTROLLED RELEASE
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
- (2010) Anne Flint et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Unique Arrangement of - and -Cells in Human Islets of Langerhans
- (2010) D. Bosco et al. DIABETES
- Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes
- (2010) J. Z. Dong et al. DIABETES OBESITY & METABOLISM
- Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
- (2010) M. Malm-Erjefalt et al. DRUG METABOLISM AND DISPOSITION
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes
- (2010) Erin L St Onge et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials
- (2010) M. A. Karsdal et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
- (2010) Ulrich Werner et al. REGULATORY PEPTIDES
- Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model
- (2009) Jens Kristensen et al. BMC Cardiovascular Disorders
- Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota
- (2009) Patrice D Cani et al. CURRENT OPINION IN PHARMACOLOGY
- Age-Dependent Decline in -Cell Proliferation Restricts the Capacity of -Cell Regeneration in Mice
- (2009) S.-I. Tschen et al. DIABETES
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
- (2009) M. A. Bush et al. DIABETES OBESITY & METABOLISM
- The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
- (2009) J. Hsieh et al. DIABETOLOGIA
- Lessons from the Crystallographic Analysis of Small Molecule Binding to Human Serum Albumin
- (2009) Stephen Curry Drug Metabolism and Pharmacokinetics
- Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy
- (2009) Morten A. Karsdal et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
- (2009) Hongbin Liu et al. JOURNAL OF ENDOCRINOLOGY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Lack of specificity of antibodies directed against human beta-adrenergic receptors
- (2009) Nazha Hamdani et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors
- (2009) Wisuit Pradidarcheep et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular evolution of mammalian incretin hormone genes
- (2009) David M. Irwin REGULATORY PEPTIDES
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
- (2008) J.-P. Courrèges et al. DIABETIC MEDICINE
- Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
- (2008) T. Vilsbøll et al. DIABETIC MEDICINE
- Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain
- (2008) Steffen Runge et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
- (2008) Felix Kratz JOURNAL OF CONTROLLED RELEASE
- Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice
- (2008) Gitte Jositsch et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Should we be cautious on the use of commercially available antibodies to dopamine receptors?
- (2008) Serena Bodei et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Engineering of a femtomolar affinity binding protein to human serum albumin
- (2008) A. Jonsson et al. PROTEIN ENGINEERING DESIGN & SELECTION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started